In particular, ivosidenib in combination with azacytidine gained approval for ND IDH1-mutated AML patients aged 75 and above or those with comorbidities following the results of the phase III AGILE trial, which included 146 patients randomly assigned to receive azacytidine plus ivosidenib or azacytidine alone [140]. Here, IDH1 is linked to acute myeloid leukemia.